New Specialty Biochemical plant inaugurated by Godavari Biorefineries Ltd
A new specialty biochemical plant has been inaugurated at the Sakarwadi manufacturing facility in Maharashtra, India where Godavari Biorefineries Limited (GBL) intends to produce biobased chemicals to support the green and net-zero ambitions of its clientele in different markets across the globe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240607431453/en/
Inauguration of new specialty biochemical plant at the Sakarwadi manufacturing facility in Maharashtra, India (Photo: Business Wire)
GBL has taken a next step with the intention to support the world’s ambition for net-zero strategies by developing a multi-purpose plant which aims to produce biobased chemicals for coatings & resins, cosmetics, pharmaceuticals and food & fragrances markets.
“At GBL we make Specialty Chemicals from Renewable Resources using Green Chemistry. We work with farmers to develop sustainable agricultural value chains that serve as a feedstock for our biobased chemicals,” said Samir Somaiya, Chairman of Somaiya Group andGodavari Biorefineries Ltd.
This multi-purpose plant is one of the steps GBL has taken to support and partner with leading companies to enlarge the amount of biobased chemical blocks in the chemical industry for different markets and products, and intends to produce biochemicals like biobutanol, biobased ethers and esters in this plant. GBL has the strategy to further develop and scale-up its capacity in the coming years in volumes and for new biobased chemicals.
“We work in close relation and collaboration with our customers to develop and produce new biobased chemical building blocks in several markets. In co-creation we work from R&D to pilot scale towards the (semi-)commercial scale of new biobased chemicals into several applications and products that can become biobased and green. It is a journey towards net-zero where we are open for new partnerships and new insights, and define pathways to take together,” said Sangeeta Srivastava, CEO of Godavari Biorefineries Ltd.
GBL is a flagship company of the diversified Somaiya group with an experience of over eight decades in the sugar industry and over six decades in the biobased chemicals industry. We work with our farmers in sugarcane and other biomass crops to create value for their communities and our customers' value chains.
Padma Vibhushan Prof. M. M. Sharma, a luminary in the field of chemical engineering, performed the ribbon-cutting ceremony and delivered an inspiring address. He highlighted the critical role of R&D in the chemical industry and complimented GBL efforts in establishing a plant that represents the future of specialty chemicals manufacturing.
For information please visit: http://godavaribiorefineries.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240607431453/en/
Contact information
E-mail: dhansoia.pushpendra@somaiya.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy – Technology Transferred from Japan27.10.2025 08:39:00 EET | Press release
Significantly extended survival and improved quality of life (QoL) for cancer patients achieved through autologous cell-based AIET immunotherapy, utilizing patients' own natural killer (NK) cells and T cells, has positioned Vinmec Hospital, Vietnam, as an emerging medical tourism destination for cancer treatment across Asian countries. This accomplishment was presented by Professor Nguyen Thanh Liem at the NCRM NICHE 2025. He acknowledged the technology transfer support from GN Corporation, Japan, enabling the implementation of standardized AIET protocols in accordance with Japanese regulations, bringing treatment access to patients at Vinmec since 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026088789/en/ Professor Nguyen Thanh Liem, Director, Institute of Stem Cell and Genetic Technology Research at Vinmec International Hospital, Hanoi, Vietnam and his team have successfully implemented the technology transfer o
METI will hold GGX Finance Summit27.10.2025 08:30:00 EET | Press release
On November 5 (Wed), the Ministry of Economy, Trade and Industry (METI) will hold the GGX Finance Summit at The Capitol Hotel Tokyu and on-line. In order to further develop discussions on transition finance, industry decarbonization, and other topics related to how business and finance contribute to decarbonization, we will promote mutual cooperation between the government, business, and financial sectors, and hold discussions to lead the international rule-making process to achieve both emission reductions and economic growth. Outline of GGX Finance Summit Date: November 5th, 2025 10:00-16:45 (JST, GMT+9:00) Venue: The Capitol Hotel Tokyu (Tokyo) (2-10-3, Nagata-cho, Chiyoda-ku, Tokyo 100-0014, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: World Business Council for Sustainable Development (WBCSD), TCFD Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation)
NITMX, Ant International and Krungthai Bank Expand Payment Connectivity Between Thailand and China via PromptPay27.10.2025 05:37:00 EET | Press release
Under the guidance of the Bank of Thailand, Ant International, a leading global digital payment, digitisation and financial technology provider and National ITMX will partner to enhance and promote payments connectivity via PromptPay, between Thai merchants and Chinese consumers, which will be launched soon. Krungthai Bank will be the settlement bank for this cross-border QR partnership. In the initial phase, Chinese travellers to Thailand can use Alipay, an Alipay+ e-wallet partner, to make QR payment at millions of local merchants by scanning the PromptPay QR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026429360/en/ The partnership will facilitate Chinese tourists’ spending in Thailand while also expanding income opportunities for small and medium-sized enterprises (SMEs) across the country. Introduced by the Bank of Thailand in 2016, and operated by NITMX, PromptPay is the national payment infrastructure of Thailan
Helical Fusion Achieves Milestone Toward Commercial Fusion Energy, Advancing to Integrated Demonstration Device27.10.2025 05:00:00 EET | Press release
Helical Fusion Co., Ltd., a world-leading developer of the Helical Stellarator, has completed a critical performance test of a high-temperature superconducting (HTS) coil—a core component of commercial fusion reactors. The company has now commenced manufacturing and construction of its integrated demonstration device, Helix HARUKA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251026597002/en/ Helical Fusion members celebrating the successful HTS test with an “HTS Graduation!” sign and graduation caps Watch the key points of this release in a 2-minute video: https://youtu.be/UhgQHfKtvow Helical Fusion is the only company in the world building upon expertise in the Helical Stellarator approach, accumulated for more than 60 years at national institutes and national universities, which has been proven to possess the optimal characteristics for commercial power generation. As the sole inheritor of this knowledge from the Nation
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura ® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis26.10.2025 02:55:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data will be presented during the Systemic and New Therapies for Atopic Dermatitis session on Sunday, October 26 at 10:55 a.m. AEDT (Saturday, October 25 at 7:55 p.m. ET) (Abstract #1177) at the 15th Georg Rajka International Symposium on Atopic Dermatitis (ISAD), held from October 24 – 26, 2025, in Melbourne. Data from TRuE-AD4, which build on previously announced topline results, show the study met its co-primary endpoints at Week 8, with a statistically significant proportion of patients achieving both a ≥75% improvement in Eczema Area and Severity Index (EASI75) score from baseline (70.0% with Opzelura vs. 18.5% with vehicle, P<0.0001) and Investi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom